Oslo, Norway, May 23, 2025 - Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, today announced the presentation of new
data from two clinical trials evaluating its cancer immunotherapy candidates --
VB10.16 and VB10.NEO, both in combination with atezolizumab (Tecentriq®), -- at
the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago,
Illinois.

The two posters highlight the potential of Nykode's targeted immunotherapy
platform in inducing robust immune responses in heavily pre-treated patient
populations across multiple tumor types, with encouraging safety profiles.

"These new data add to the growing body of clinical evidence supporting our
vaccine candidates VB10.NEO and VB10.16," said Agnete Fredriksen, CSO and
Co-founder of Nykode Therapeutics. "The quality of the immune responses seen in
both trials and the increased understanding of the relation between the immune
responses and patient characteristics-reinforce the potential of our
APC-targeted technology and help define the best path forward for these
promising assets."


Sunday, June 1, 2025 | 9:00 AM-12:00 PM CT

Abstract #: 5538
Title: Integrative analysis of VB10.16 and atezolizumab in advanced
HPV16-positive cervical cancer: Linking biomarker insights to clinical outcomes.
Presenter: Kristina Lindemann, Department of Gynecological Oncology, Oslo
University Hospital & Institute of Clinical Medicine, Faculty of Medicine,
University of Oslo, Oslo, Norway
Session Type and Title: Poster Session - Gynecologic Cancer
Poster Board Number: 436
o	In patients with persistent, recurrent, or metastatic HPV16-positive cervical
cancer, VB10.16 combined with atezolizumab induced durable clinical responses.
o	The VB C-02 trial demonstrated that stronger HPV16-specific T cell responses
were associated with reduced systemic immunosuppression during treatment.
o	Tumor microenvironment (TME) characteristics are associated with higher
response rates.
o	These findings support the importance of identifying the right patient
population as well as elucidating the treatment effect on the systemic
immunosuppression and highlights the promise of VB10.16 in combination with
atezolizumab, warranting further exploration.


Monday, June 2, 2025 | 1:30 PM-4:30 PM CT

Abstract #: 2639
Title: Induction of neoantigen-specific immune responses by VB10.NEO in
combination with atezolizumab in heavily pretreated patients with advanced solid
tumors: Final analysis of the phase 1b VB N-02 trial.
Presenter: Sebastian Ochsenreither, Charité University of Medicine Berlin
Comprehensive Cancer Center, Berlin, Germany
Session Type and Title: Poster Session - Developmental Therapeutics -
Immunotherapy
Poster Board Number: 286
o	VB10.NEO, Nykode's personalized cancer neoantigen vaccine, in combination with
atezolizumab, induced neoantigen-specific immune responses.
o	Neoantigen-specific immune responses were observed in 100% of the patients and
de novo immune responses were observed in 85% of patients, as measured by in
vitro stimulated IFN ELISpot.
o	Expansion of durable T cell clones was seen in 82% of patients, suggesting
persistence of the immune response.
o	The trial enrolled heavily pre-treated patients across more than 10
indications, a median of 5 prior therapy lines and predominantly low or negative
PD-L1 expression resulting in a median PFS reached before 2 months, limiting the
opportunity for thorough assessment of long-term immune responses and clinically
meaningful responses. 
o	VB10.NEO in combination with atezolizumab demonstrated a favorable safety
profile.
o	These results support further development of VB10.NEO in additional solid
tumor settings.


The posters will be available on the Nykode website on May 30, at:
https://nykode.com/research-and-development/scientific-papers-and-presentations.

 

About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies with a focus on the
treatment of cancer and autoimmune diseases. Nykode's modular immunotherapy
technology specifically targets antigens to antigen presenting cells (APC),
which have been shown to induce a broad, strong and long-lasting antigen
specific immune response in cancer, which correlates with clinical responses.

Nykode's lead product candidates are VB10.16, a therapeutic immunotherapy for
the treatment of HPV16 induced malignancies which demonstrated favorable safety
and efficacy results from its Phase 2 trial for the treatment of cervical
cancer. VB10.16 is currently being further developed in head and neck cancer.
VB10.NEO, an individualized cancer neoantigen immunotherapy, has been
investigated in two trials with more than 10 different indications. 

Nykode is also utilizing its APC-targeted technology to create an immune
tolerance platform for the potential use in autoimmune disorders, organ
transplant rejections, anti-drug antibody reactions and allergy.

Nykode Therapeutics' shares are traded on the Oslo Stock Exchange (OSE: NYKD).
Further information about Nykode Therapeutics can be found at
http://www.nykode.com.


Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by these forward-looking statements.


Contact for Nykode Therapeutics ASA:
Alexandra Deschner, Head of IR
Nykode Therapeutics ASA 
[email protected]

Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway